206 related articles for article (PubMed ID: 35476631)
1. Effect of a single dose of 8 mg moxidectin or 150 μg/kg ivermectin on O. volvulus skin microfilariae in a randomized trial: Differences between areas in the Democratic Republic of the Congo, Liberia and Ghana and impact of intensity of infection.
Bakajika D; Kanza EM; Opoku NO; Howard HM; Mambandu GL; Nyathirombo A; Nigo MM; Kennedy KK; Masembe SL; Mumbere M; Kataliko K; Bolay KM; Attah SK; Olipoh G; Asare S; Vaillant M; Halleux CM; Kuesel AC
PLoS Negl Trop Dis; 2022 Apr; 16(4):e0010079. PubMed ID: 35476631
[TBL] [Abstract][Full Text] [Related]
2. Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia.
Kanza EM; Nyathirombo A; Larbelee JP; Opoku NO; Bakajika DK; Howard HM; Mambandu GL; Nigo MM; Wonyarossi DU; Ngave F; Kennedy KK; Kataliko K; Bolay KM; Attah SK; Olipoh G; Asare S; Mumbere M; Vaillant M; Halleux CM; Kuesel AC
Parasit Vectors; 2024 Mar; 17(1):137. PubMed ID: 38491528
[TBL] [Abstract][Full Text] [Related]
3. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial.
Opoku NO; Bakajika DK; Kanza EM; Howard H; Mambandu GL; Nyathirombo A; Nigo MM; Kasonia K; Masembe SL; Mumbere M; Kataliko K; Larbelee JP; Kpawor M; Bolay KM; Bolay F; Asare S; Attah SK; Olipoh G; Vaillant M; Halleux CM; Kuesel AC
Lancet; 2018 Oct; 392(10154):1207-1216. PubMed ID: 29361335
[TBL] [Abstract][Full Text] [Related]
4. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.
Awadzi K; Opoku NO; Attah SK; Lazdins-Helds J; Kuesel AC
PLoS Negl Trop Dis; 2014 Jun; 8(6):e2953. PubMed ID: 24968000
[TBL] [Abstract][Full Text] [Related]
5. Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density.
Siewe Fodjo JN; Mandro M; Mukendi D; Tepage F; Menon S; Nakato S; Nyisi F; Abhafule G; Wonya'rossi D; Anyolito A; Lokonda R; Hotterbeekx A; Colebunders R
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007300. PubMed ID: 31314757
[TBL] [Abstract][Full Text] [Related]
6. Onchocerca volvulus and O. lienalis: the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo.
Tagboto SK; Townson S
Ann Trop Med Parasitol; 1996 Oct; 90(5):497-505. PubMed ID: 8915126
[TBL] [Abstract][Full Text] [Related]
7. Onchocerca volvulus as a risk factor for developing epilepsy in onchocerciasis endemic regions in the Democratic Republic of Congo: a case control study.
Mandro M; Suykerbuyk P; Tepage F; Rossy D; Ngave F; Hasan MN; Hotterbeekx A; Mambandu G; Kashama JM; Laudisoit A; Colebunders R
Infect Dis Poverty; 2018 Oct; 7(1):79. PubMed ID: 30293530
[TBL] [Abstract][Full Text] [Related]
8. Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial.
Mandro M; Siewe Fodjo JN; Mukendi D; Dusabimana A; Menon S; Haesendonckx S; Lokonda R; Nakato S; Nyisi F; Abhafule G; Wonya'Rossi D; Jakwong JM; Suykerbuyk P; Meganck J; Hotterbeekx A; Colebunders R
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007966. PubMed ID: 31923177
[TBL] [Abstract][Full Text] [Related]
9. Assessing
Hedtke SM; Choi YJ; Kode A; Chalasani GC; Sirwani N; Jada SR; Hotterbeekx A; Mandro M; Siewe Fodjo JN; Amambo GN; Abong RA; Wanji S; Kuesel AC; Colebunders R; Mitreva M; Grant WN
Pathogens; 2023 Jul; 12(7):. PubMed ID: 37513818
[TBL] [Abstract][Full Text] [Related]
10. Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?
Kura K; Milton P; Hamley JID; Walker M; Bakajika DK; Kanza EM; Opoku NO; Howard H; Nigo MM; Asare S; Olipoh G; Attah SK; Mambandu GL; Kennedy KK; Kataliko K; Mumbere M; Halleux CM; Hopkins A; Kuesel AC; Kinrade S; Basáñez MG
Philos Trans R Soc Lond B Biol Sci; 2023 Oct; 378(1887):20220277. PubMed ID: 37598705
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of epilepsy in onchocerciasis endemic regions in the Democratic Republic of the Congo.
Levick B; Laudisoit A; Tepage F; Ensoy-Musoro C; Mandro M; Bonareri Osoro C; Suykerbuyk P; Kashama JM; Komba M; Tagoto A; Falay D; Begon M; Colebunders R
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005732. PubMed ID: 28708828
[TBL] [Abstract][Full Text] [Related]
12. Histological examination of onchocercomata after therapy with ivermectin.
Albiez EJ; Walter G; Kaiser A; Ranque P; Newland HS; White AT; Greene BM; Taylor HR; Büttner DW
Trop Med Parasitol; 1988 Jun; 39(2):93-9. PubMed ID: 3175472
[TBL] [Abstract][Full Text] [Related]
13. A Reevaluation of the Tolerability and Effects of Single-Dose Ivermectin Treatment on Onchocerca volvulus Microfilariae in the Skin and Eyes in Eastern Ghana.
Opoku NO; Gyasi ME; Doe F; Lew D; Hong AR; Chithenga S; Fischer PU; King CL; Weil GJ
Am J Trop Med Hyg; 2021 Nov; 106(2):740-745. PubMed ID: 34844204
[TBL] [Abstract][Full Text] [Related]
14. Moxidectin: an oral treatment for human onchocerciasis.
Milton P; Hamley JID; Walker M; Basáñez MG
Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1067-1081. PubMed ID: 32715787
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection.
Tan B; Opoku N; Attah SK; Awadzi K; Kuesel AC; Lazdins-Helds J; Rayner C; Ryg-Cornejo V; Sullivan M; Fleckenstein L
PLoS Negl Trop Dis; 2022 Mar; 16(3):e0010005. PubMed ID: 35333880
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of epilepsy in onchocerciasis endemic health areas in Democratic Republic of the Congo.
Lenaerts E; Mandro M; Mukendi D; Suykerbuyk P; Dolo H; Wonya'Rossi D; Ngave F; Ensoy-Musoro C; Laudisoit A; Hotterbeekx A; Colebunders R
Infect Dis Poverty; 2018 Aug; 7(1):68. PubMed ID: 30064504
[TBL] [Abstract][Full Text] [Related]
17. Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo.
Makenga Bof JC; Muteba D; Mansiangi P; Ilunga-Ilunga F; Coppieters Y
BMC Pharmacol Toxicol; 2019 Aug; 20(1):49. PubMed ID: 31420005
[TBL] [Abstract][Full Text] [Related]
18. Onchocerciasis control in the Democratic Republic of Congo (DRC): challenges in a post-war environment.
Makenga Bof JC; Maketa V; Bakajika DK; Ntumba F; Mpunga D; Murdoch ME; Hopkins A; Noma MM; Zouré H; Tekle AH; Katabarwa MN; Lutumba P
Trop Med Int Health; 2015 Jan; 20(1):48-62. PubMed ID: 25302560
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of moxidectin 2% equine oral gel and ivermectin 2% equine oral paste against Onchocerca cervicalis (Railliet and Henry, 1910) microfilariae in horses with naturally acquired infections in Formosa (Argentina).
Mancebo OA; Verdi JH; Bulman GM
Vet Parasitol; 1997 Dec; 73(3-4):243-8. PubMed ID: 9477510
[TBL] [Abstract][Full Text] [Related]
20. Differential susceptibility of Onchocerca volvulus microfilaria to ivermectin in two areas of contrasting history of mass drug administration in Cameroon: relevance of microscopy and molecular techniques for the monitoring of skin microfilarial repopulation within six months of direct observed treatment.
Abong RA; Amambo GN; Chounna Ndongmo PW; Njouendou AJ; Ritter M; Beng AA; Esum ME; Deribe K; Fru-Cho J; Fombad FF; Nji TM; Enyong PI; Poole CB; Pfarr K; Hoerauf A; Carlow CKS; Wanji S
BMC Infect Dis; 2020 Oct; 20(1):726. PubMed ID: 33008333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
